ThromboGenics appoints Dr David Guyer to its Board of Directors

– BELGIUM, Leuven – ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today the appointment of Dr David Guyer to its Board of Directors.…